Home » Research Area » » 7-TM Receptors » GPR35 » NPPB

NPPB

Cat. No. 0593

Price and Availability

For NPPB pricing & availability please select your country from the drop down menu:
Submit

By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: 5-Nitro-2-(3-phenylpropylamino)benzoic acid

Biological Activity

Very potent chloride channel blocker. Putative GPR35 agonist.

Technical Data

M.Wt:

300.31

Formula:

C₁₆H₁₆N₂O₄

Solubility:

Soluble to 100 mM in DMSO and to 20 mM in ethanol

Purity:

>99 %

Storage:

Store at RT

CAS No:

107254-86-4

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Resources

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch

Safety Data Sheet: View Safety Data Sheet

References

Wangemann et al (1986) Cl^--channel blockers in the thick ascending limb of the loop of Henle. Structure-activity relationship. Pflugers Arch. 407 S128. PMID: 2434915.

Keeling et al (1991) Effects of NPPB (5-nitro-1-(3-phenylpropylamino)benzoic acid on chloride transport in intestinal tissues and the T₈₄ cell line. Biochim.Biophys.Acta 115 42. PMID: 1720331.

Kirkup et al (1996) Investigation of the effects of 5-nitro-2-(3-phenylpropylamino)-benzoic acid (NPPB) on membrane currents in rat portal vein. Br.J.Pharmacol. 117 175. PMID: 8825360.

Taniguchi et al (2008) 5-nitro-2-(3-phenylpropylamino)benzoic acid is a GPR35 agonist Pharmacology 82 245. PMID: 18818509.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

Chloride Channels

GPR35

Keywords: NPPB, supplier, Chloride, channel, blockers, Cl-, Channels

Quick Order

Find multiple products by catalog number

7-TM Receptor Signaling

Written by T. Kenakin et al

'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy